Risk factors

Heavy reliance on key executive Sardar Biglari who controls over fifty percent of voting stock. Operations span restaurants, insurance, investment partnerships, oil and gas, and brand licensing.

Biohaven faces substantial operating losses, with a net loss of $846.4 million in 2024 and no product revenues to date. The company relies heavily on third-party suppliers, clinical trial outcomes, and patent protection for candidates like troriluzole and taldefgrobep alfa.

Single-source suppliers manufacture critical bioproduction components for cell and gene therapies.

BRC Inc. faces significant concentration risk with its primary Wholesale partners representing 63% of net sales in 2024. The company relies heavily on maintaining brand authenticity within the Veteran community and its co-manufacturing supply chain. Substantially all corporate deposits are held with a single bank.

Sierra Bancorp faces heavy exposure to real estate loan concentrations, regulatory restrictions on emerging businesses, and potential credit losses from economic volatility.

Litigation outcome unpredictability and illiquidity dominate risk factors. Capital commitments frequently exceed available funds, creating financing pressure. Fair value accounting introduces unrealized non-cash income volatility.

Topgolf Callaway Brands faces significant risk from discretionary spending trends, same venue sales declines, and labor cost pressures.

Substantial debt load and floating interest rates expose the company to significant financial pressure from market conditions. International operations generate 63 percent of net sales, creating foreign exchange and emerging market risks. Raw material price volatility for aluminum, steel, and energy directly threatens profit margins.

Aluminum price volatility and global overproduction heavily impact financial performance and operational viability. Electricity costs and power supply disruptions threaten smelting operations across facilities. Heavy customer concentration with Glencore represents a primary revenue dependency. Substantial debt obligations require significant cash flow and limit operational flexibility.

ChronoScale faces going concern doubts with $6.5M in cash and a $250.5M accumulated deficit. The business relies heavily on VA hospitals, DME suppliers, and third-party reimbursement for EksoNR and Ekso Indego products. Strict FDA, EU MDR, and debt covenants under the Banc of California agreement constrain operations.

Calumet carries significant debt of $2.1 billion alongside $441.8 million at its unrestricted subsidiary Montana Renewables. Operations face heavy commodity price volatility, including Gulf Coast crack spread fluctuations. Environmental compliance, renewable fuel mandates, and labor relations under unionized agreements are central risks.

Clover Health faces significant financial risks, including past net losses totaling $46.3 million in 2024 and an accumulated deficit of $2.2 billion.